Prescription Drug Prices: Analysis of Canada's Patented Medicine Prices Review Board
HRD-93-51 Published: Feb 17, 1993. Publicly Released: Feb 22, 1993.
Skip to Highlights
Pursuant to a congressional request, GAO: (1) described the purpose and structure of Canada's Patented Medicine Prices Review Board as well as its guidelines and procedures, especially those used to determine if a drug price is excessive; and (2) summarized the evidence about the effects of the Board's actions on the prices of new drugs, on price increases for existing drugs, and on pharmaceutical research and development.